Investment Rating - The report suggests focusing on globally competitive CXO companies such as WuXi AppTec, WuXi XDC Cayman, WuXi Biologics Cayman, Pharmaron, Asymchem Laboratories, Porton Pharma Solutions, and Zhejiang Jiuzhou Pharmaceutical [29][30] Core Insights - The overseas CXO industry has confirmed a bottom in prosperity and is showing signs of structural recovery. The industry has passed the cyclical bottom, but recovery is characterized by significant structural differentiation [30] - Clinical CROs like IQVIA and Medpace are leading the recovery with strong orders and guidance, while CDMOs such as Lonza demonstrate resilience through long-term contracts. Preclinical CROs and research services are still stabilizing, with improving inquiry or order cancellation rates [30][31] - The overall recovery strength and sustainability will depend on the continuation of enthusiasm in biotech financing [30] Summary by Sections 1. Overseas CXO Industry Q3 2025 Performance Review - The overseas CXO industry has shown a structural recovery trend, with significant differentiation in recovery across sectors. Clinical CROs are leading the recovery, while preclinical CROs and research services are still in a stabilization phase [8][30] 2. Leading Company Analysis 2.1 Charles River - The company is nearing a performance bottom, with Q3 revenue at $1 billion and an organic growth rate of -1.6%. The management has raised the full-year revenue and EPS guidance, indicating a positive outlook for 2026 [15][16] 2.2 Samsung Biologics - The company reported a strong Q3 performance with revenue of 1.66 trillion KRW, a 40% YoY increase. The CDMO segment continues to grow, with a full-year revenue growth guidance of 25%-30% [19][20] 2.3 Lonza - Lonza's Q3 performance met expectations, with CDMO business projected to grow by 20%-21% YoY. The company is experiencing strong demand in its core business segments [24][25] 3. Key Financial Metrics - The report includes financial forecasts for various companies, indicating expected revenue growth and profitability metrics for 2025-2027. For instance, WuXi AppTec is expected to have an EPS of 5.42 in 2025, with a PE ratio of 18 [26]

Core Viewpoint - Investors are increasingly seeking growth stocks that demonstrate above-average growth potential, with Medpace (MEDP) identified as a strong candidate due to its favorable growth metrics and Zacks Rank [2][10] Group 1: Earnings Growth - Medpace has a historical EPS growth rate of 32%, with projected EPS growth of 17.1% for the current year, surpassing the industry average of 15.7% [4] - The importance of double-digit earnings growth is emphasized as a key indicator of strong company prospects and potential stock price gains [3] Group 2: Cash Flow Growth - Medpace's year-over-year cash flow growth stands at 40.3%, significantly higher than the industry average of -1.2%, indicating robust financial health [5] - The company's annualized cash flow growth rate over the past 3-5 years is 26%, compared to the industry average of 7.7%, showcasing its superior performance [6] Group 3: Earnings Estimate Revisions - There has been a positive trend in earnings estimate revisions for Medpace, with the Zacks Consensus Estimate for the current year increasing by 5.3% over the past month [8] - The correlation between earnings estimate revisions and near-term stock price movements supports the stock's potential for growth [7]

Core Insights - U.S. stocks experienced a rally in Q3, supported by the Federal Reserve's interest rate cut and steady economic data, with the Russell Midcap® Growth Index increasing by 2.78% [3][17] - The Wasatch U.S. Select Fund underperformed, declining by -1.93%, primarily due to concentrated holdings in stocks that faced slower revenue growth [3][4][17] Fund Performance Analysis - The Fund's performance was negatively impacted by a few concentrated stock holdings that reported slower revenue growth, leading to significant declines in their stock prices [4][6] - The investment strategy focuses on high-quality, long-duration growth companies, which faced headwinds as low-quality stocks gained favor in the market [7] Key Detractors - BellRing Brands, Inc. (BRBR) was the largest detractor, with concerns over competition in the protein shake category; however, the long-term outlook remains positive due to category growth potential [8] - Shift4 Payments, Inc. (FOUR) faced stock price declines despite solid organic revenue growth, attributed to macroeconomic concerns and investor sentiment following its acquisition of Global Blue [9] - Inspire Medical Systems, Inc. (INSP) was sold during the quarter after management downgraded guidance due to delays in product rollout, raising execution concerns [10] Top Contributors - Medpace Holdings, Inc. (MEDP) was the top contributor, with strong revenue and earnings growth, raising full-year guidance despite a slowdown in biotech funding [11] - Fabrinet (FN) benefited from strong product adoption, particularly in data centers linked to AI, although the investment is not solely based on AI themes [12] - Nova Ltd. (NVMI) also contributed positively, with a strong track record in semiconductor manufacturing, benefiting from increasing complexity in the industry [13] Future Outlook - The Fund remains committed to its investment philosophy, focusing on high-quality growth companies despite recent underperformance [14] - The fundamentals of the companies within the Fund are encouraging, with strong earnings growth expected to drive return potential over a three- to five-year horizon [15]

Group 1: Company Performance - Jacobs Solutions stock had its Relative Strength (RS) Rating upgraded from 70 to 74, indicating a welcome improvement but still below the desired score of 80 or higher [2] - Jacobs Solutions has met the benchmark of an 80-plus Relative Strength Rating, reflecting improved market leadership [5] Group 2: Industry Trends - The surge in demand for electricity is driven by the explosion in data centers for artificial intelligence, highlighting a significant trend in the industry [3] - Stocks related to AI data centers are showing strong performance, with some stocks identified as being in buy zones due to this trend [2]

Group 1: Market Performance - The Hong Kong Innovative Drug Selected ETF (520690) increased by 0.22%, with the latest price at 0.89 yuan as of October 29, 2025 [3] - The ETF recorded a turnover of 4.25% during the trading session, with a total transaction value of 21.78 million yuan [3] - Over the past year, the average daily transaction volume of the ETF was 120 million yuan [3] Group 2: Clinical Data and Industry Insights - Grail presented initial data from its multi-cancer early detection product Galleri at the 2025 ESMO annual meeting, showing a positive predictive value of 61.6% and a specificity of 99.6% [3] - Among the detected new cancers, 69.3% were in stages I-III, with a tissue origin accuracy of 91.7% [3] - Guosen Securities views this data as a significant milestone in the multi-cancer early detection field, suggesting Galleri could enhance existing screening systems [3] Group 3: Company Earnings and Trends - Over 280 pharmaceutical and biotech companies, including Heng Rui Pharmaceutical and WuXi AppTec, reported strong Q3 results, driven by advancements in R&D pipelines and new drug launches [3] - The overall industry is exhibiting a positive trend characterized by "innovation as a foundation and overseas expansion" [3] Group 4: CDMO Sector Performance - Lonza, a leading overseas CDMO, reported strong Q3 results, maintaining a revenue growth forecast of 20-21% for the year, with core EBITDA margins between 30-31% [4] - Medpace has seen consecutive growth in new orders for two quarters, indicating a recovering financing environment for U.S. small and mid-sized biotech firms [4] - WuXi AppTec exceeded Q3 performance expectations and raised its full-year guidance, further confirming the positive outlook for the CXO industry [4] Group 5: ETF Size and Inflows - The latest size of the Hong Kong Innovative Drug Selected ETF reached 512 million yuan, marking a new high since its inception [4] - The ETF's share count also hit a record high of 574 million shares [4] - In the past five days, the ETF experienced continuous net inflows, with a peak single-day net inflow of 31.48 million yuan, totaling 82.81 million yuan in net inflows [4]

Core Viewpoint - Medpace (MEDP) has received an upgrade to a Zacks Rank 1 (Strong Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][2]. Earnings Estimates and Stock Performance - The Zacks rating system emphasizes the importance of changing earnings estimates in determining stock price movements, making it a valuable tool for investors [2][3]. - A strong correlation exists between earnings estimate revisions and near-term stock movements, with institutional investors playing a role in this relationship by adjusting their valuations based on earnings estimates [3]. Medpace's Earnings Outlook - Medpace is projected to earn $14.79 per share for the fiscal year ending December 2025, with no year-over-year change expected [7]. - Over the past three months, the Zacks Consensus Estimate for Medpace has increased by 5.7%, reflecting analysts' positive revisions [7]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [6]. - Medpace's upgrade to Zacks Rank 1 places it in the top 5% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [9].

Core Insights - Three stocks are highlighted with strong buy rankings and positive momentum characteristics for investors to consider on October 28th Company Summaries Medpace (MEDP) - Medpace is a global, full-service clinical contract research organization providing Phase I-IV clinical development services to the biotechnology, pharmaceutical, and medical device industries - The company has a Zacks Rank of 1 (Strong Buy) and the Zacks Consensus Estimate for its current year earnings has increased by 3.6% over the last 60 days - Medpace's shares have gained 31.7% over the last three months, significantly outperforming the S&P 500's gain of 7.6%, and it possesses a Momentum Score of A [1][2] Vertiv (VRT) - Vertiv is a leading global provider of critical digital infrastructure and services for data centers, communication networks, and commercial and industrial environments - The company also holds a Zacks Rank of 1 and has seen the Zacks Consensus Estimate for its current year earnings increase by 7.6% over the last 60 days - Vertiv's shares have increased by 35.4% over the last three months, again outperforming the S&P 500's gain of 7.6%, and it has a Momentum Score of A [2][3] TakeTwo Interactive Software (TTWO) - TakeTwo Interactive Software is a leading developer and publisher of video games - The company has a Zacks Rank of 1, with the Zacks Consensus Estimate for its current year earnings rising by 0.7% over the last 60 days - TakeTwo's shares have gained 12.4% over the last three months, surpassing the S&P 500's gain of 7.6%, and it has a Momentum Score of B [3][4]

Core Insights - Medpace Holdings Inc. reported better-than-expected third-quarter earnings, with earnings of $3.86 per share, surpassing the consensus estimate of $3.52 [1] - The company's sales reached $659.9 million, exceeding the consensus of $640.99 million, marking a year-over-year increase of 23.7% [1] - On a constant currency basis, revenue increased by 23.4% [1] Financial Guidance - Medpace raised its fiscal 2025 earnings per share guidance from a range of $13.76-$14.53 to $14.60-$14.86, compared to the consensus of $14.07 [2] - The sales guidance for 2025 was also increased from $2.42 billion-$2.52 billion to $2.48 billion-$2.53 billion, against a consensus of $2.46 billion [2] Stock Performance - Following the earnings announcement, Medpace shares rose by 1% to trade at $602.08 [2] - Analysts adjusted their price targets for Medpace, with Mizuho maintaining an Outperform rating and raising the target from $575 to $655, while Barclays maintained an Underweight rating and increased the target from $425 to $485 [4]

Group 1 - The article discusses the Biotech Analysis Central service, which provides in-depth analysis of pharmaceutical companies and offers a model portfolio of small and mid-cap stocks [1][2] - The service includes over 600 biotech investing articles and live chat features to assist healthcare investors in making informed decisions [2] - A promotional offer is available for new subscribers, including a two-week free trial and a discounted annual subscription price [1] Group 2 - The author of the article has no current stock or derivative positions in any mentioned companies and does not plan to initiate any within the next 72 hours [3] - The article expresses the author's personal opinions and is not compensated beyond the Seeking Alpha platform [3] - Seeking Alpha clarifies that past performance does not guarantee future results and that the views expressed may not reflect the platform's overall stance [4]

Group 1 - Crude oil prices increased by 5% following a significant move by Trump, impacting market sentiment [1] - Dow Jones Industrial Average and other major stock indexes experienced a decline in premarket trading, with the Dow dropping 0.2% and S&P 500 futures also down 0.2% [1] - Tesla's stock fell after the company reported disappointing third-quarter results, contributing to a broader market decline [1] Group 2 - Medpace's stock surged due to strong quarterly performance, reporting double-digit sales and profit growth along with a guidance hike [2]